Salute e Benessere

Santhera Publishes Agenda for its Annual General Meeting

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on June 18, 2024, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland.The invitation to the AGM with agenda items and explanations will be sent to registered shareholders by mail and can be viewed on Santhera's website at...
Nasdaq GlobeNewswire
28/05/2024

Santhera Publishes Annual Report 2023

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2023 with fully audited results for the year ended December 31, 2023.Santhera's Annual Report 2023 provides comprehensive and detailed information on the Company, its strategy, business, financial performance, governance and compensation in 2023, and confirms the preliminary unaudited 2023 annual results which were published...
Nasdaq GlobeNewswire
28/05/2024

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's first quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152International: 1-201-389-0879Conference ID: 13746795Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1672725&tp_key=f83e7ab481About Cellectis ...
Nasdaq GlobeNewswire
27/05/2024

Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X…

Infographic - https://mma.prnewswire.com/media/2422871/Figure_A_Infographic.jpg Infographic -https://mma.prnewswire.com/media/2422871/Figure_A_Infographic.jpg Management Comments Iris Bincovich, the CEO of Innocan commented: "Our LPT-CBD technology has made strong advancements in the past few months. We very much look forward to our upcoming meeting with the FDA in July where they will review and advise on our clinical plan for bringing our LPT-CBD technology to market for...
PR Newswire
27/05/2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities…

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 27, 2024 – 07:00 PM CET(Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on May 24, 2024, from Atlas Special Opportunities, LLC indicating that as of May 22, 2024, it held 2,377,763,043...
Nasdaq GlobeNewswire
27/05/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of April 30, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (May 27, 2024 - 6:00 pm)– As of April 30, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks...
Nasdaq GlobeNewswire
27/05/2024

Personalized Medicine Market Size to Worth USD 152.40 Bn By 2031

The increasing adoption of personalized medicine and growing demand for personalized healthcare are the major factors driving the growth of the personalized medicine market. Personalized medicine considers individual lifestyle, environmental, and genetic differences and helps healthcare providers customize medical treatment accordingly. It is more effective in diagnosing, preventing, and treating diseases in individuals compared to traditional medicine, which follows a…
PR Newswire
27/05/2024

BioSenic S.A. : Positive vote of the majority of creditors in favor of the…

PRESS RELEASE - PRIVILEGED INFORMATIONAfter a recent circular consultation of the creditors, based on XX 83/23 of the Economic Law Code (ELC), the Enterprise Court of Nivelles registers today the positive votes of the majority of creditors on the Restructuration Plan presented by BioSenic and its restructuration practitioner, Maître Yves Brulard. Mont-Saint-Guibert, Belgium, 27 May 2024, 5:00pm CET –BioSenic(Euronext Brussels and Paris: BIOS),the clinical-stage company...
Nasdaq GlobeNewswire
27/05/2024

New "Barbora" CEO - Povilas Šulys

On Tuesday, May 28th, Povilas Šulys will assume the roles of director of UAB "Barbora" and director and board member of its managing company RADAS, UAB. P. Šulys succeeds Viktoras Juozapaitis, who decided to leave the "Vilniaus prekyba" group of companies, where he had been working since 2020. P. Šulys has been working in various group companies since 2016, having led "Franmax," "Ermi group," and "Ermitažas." For the past year and a half, he…
Nasdaq GlobeNewswire
27/05/2024

Preclinical Imaging Market Worth $1,259 million | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841 Browse in-depth TOC on "Preclinical Imaging Market" 83 - Tables40 - Figures165 - Pages Preclinical Imaging Market Scope: Optical Imaging reagents segment is the largest product type of the preclinical reagents market in 2023. Based on reagents, the preclinical imaging...
PR Newswire
27/05/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from May 20, 2024 to May 24, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
27/05/2024

Orthopedic Surgical Robots Market Worth US$ 8.34 Billion by 2034: Fact.MR

The number of surgical procedures conducted each year is increasing across the world, leaving surgeons to have to execute more difficult and time-consuming procedures. Fractures are becoming one of the main forces behind the increased demand for robotic arms; these robotic arms can print a 3D image of the shattered bone fragment, allowing surgeons to connect the 3D portion to the wounded location and treat the patient. The number of surgical procedures conducted each year is increasing across...
PR Newswire
27/05/2024

Global Immunoassay Market to Witness Growth at a CAGR of ~8% by 2030 |…

Key Takeaways from the Immunoassay Market Report Key Takeaways from the Immunoassay Market Report To read more about the latest highlights related to the immunoassay market, get a snapshot of the key highlights entailed in theGlobal Immunoassay Market Report Immunoassay Overview Immunoassay, a cornerstone in medical diagnostics, revolutionizes the detection of various substances within biological samples through the utilization of the immune system's remarkable specificity...
PR Newswire
27/05/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 27 May 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the…
Nasdaq GlobeNewswire
27/05/2024

Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines…

Key Takeaways from the Acne Vulgaris Market Report Key Takeaways from the Acne Vulgaris Market Report Discover which therapies are expected to grab the major acne vulgaris market share @Acne Vulgaris Market Report Acne Vulgaris Overview Acne vulgaris, commonly known as acne, is a prevalent skin condition that affects millions of people worldwide, typically during adolescence but can persist into adulthood. It occurs when hair follicles become clogged with oil and dead skin...
PR Newswire
27/05/2024

Helsinn and Angelini Pharma sign a partnership agreement renewal to…

Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN ®and MESULID ®in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak RepublicLugano (Switzerland) and Rome (Italy)– May 27, 2024– Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Angelini Pharma (“Angelini”), an...
Nasdaq GlobeNewswire
27/05/2024

Hisense Welcomes Goalkeeping Icon Iker Casillas Fernández to UEFA EURO 2024™…

"I am delighted to partner with Hisense and join the 'BEYOND GLORY' campaign which puts the spotlight on celebrating the world's best goalkeepers," explained Iker Casillas. "A goalkeeper's winning reputation is based on their reliability. I am pleased to be invited by Hisense as a Global Ambassador, representing a company relied on by its customers for creating innovative technology that improves their lives." "I am delighted to partner with Hisense and join the 'BEYOND…
PR Newswire
27/05/2024

Changes to the Roche Enlarged Corporate Executive Committee

James Sabry joined Genentech in 2010 as Head of Genentech Partnering. In 2018, he became the Head of Pharma Partnering and a member of the enlarged Corporate Executive Committee, based in Basel, Switzerland. James Sabry completed an MD at Queen's University in Canada and his residency at Harvard Medical School, and then completed a PhD in neuroscience at UCSF. Boris Zaïtra (1972), currently Head of Group Business Development, will be appointed Head of Corporate Business Development...
Nasdaq GlobeNewswire
27/05/2024

Press Release: Sarclisa accepted for FDA priority review for the treatment of…

Sarclisaaccepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaFDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of...
Nasdaq GlobeNewswire
27/05/2024

Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for…

"I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care", commented Palani Kumaresan, Head of Roche Diagnostic Solutions. "Together, we have built an unrivalled installed base of more than 84,000 diagnostic platforms around the globe. This brings both speed and scale to testing for our customers, helping them to better serve patients' needs." "I am delighted that with…
PR Newswire
27/05/2024

Celebrate International Skin Pigmentation Day with Cyspera Boost™

Isobionic Amide: A Beacon of InnovationDeveloped by Dr. B. Kasraee, Isobionic-Amide was identified through careful analysis of the chemical structure of other depigmenting agents, including phenols. Isobionic-Amide has been shown to be the most potent isomer of niacinamide for reduction of the melanin production, resulting in significant depigmentation and enhanced skin brightness. It is recognized as a safe and highly effective molecule for reducing unwanted pigmentation. Isobionic Amide: A...
PR Newswire
25/05/2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria…

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks 1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN 2-5 ; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient...
Nasdaq GlobeNewswire
25/05/2024

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3…

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3 Fabhalta showed a favorable safety profile with no new safety signals 1 C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years 4-7 ; currently there are no...
Nasdaq GlobeNewswire
25/05/2024

Appointment of new CFO

ANNOUNCEMENT NO. 269 Appointment of new CFOThe board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024.Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY.The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen...
Nasdaq GlobeNewswire
24/05/2024
Altri  Comunicati